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Neuroﬁbrillary tanglesAlzheimer's dementia is developing ever more as a complex syndrome with various unknown genetic and
epigenetic contributions. These are compounded on and exacerbating the underlying amyloid and tau pathology
that remain the basis of the pathological deﬁnition of Alzheimer's disease. Here, we present a selection of aspects
of recent bigenic and virus-based mouse strains, developed as pre-clinical models for Alzheimer's disease. We
discuss newer features in the context of the characteristics deﬁned in previously validated transgenicmodels.We
focus on speciﬁc aspects of single and multiple transgenic mouse models for Alzheimer's disease and for
tauopathies, rather than providing an exhaustive list of all available models. We concentrate on the content of
information related to neurodegeneration and diseasemechanisms.We pay attention to aspects and defects that
are predicted by the models and can be tested in humans. We discuss implications that help translate the
fundamental knowledge into clinical, diagnostic and therapeutic applications. We elaborate on the increasing
knowledge extracted from transgenic models and from newer adeno-associated viral models. We advocate this
combination as a valuable strategy to studymolecular, cellular and system-related pathogenicmechanisms inAD
and tauopathies. We believe that innovative animal models remain needed to critically test current views, to
identify and validate therapeutic targets, to allow testing of compounds, to help understand and eventually treat
tauopathies, including Alzheimer's disease., LEGTEGG, KULeuven, Campus
en, Belgium. Tel.: +32 16 345
. Van Leuven).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction and background
1.1. Alzheimer disease
Alzheimer's disease (AD) is the most prevalent form of dementia
among the elderly accounting for more than 70% of all dementia cases
[1]. The clinical disease stages are initially announced by mild
cognitive impairment (MCI) that gradually progresses from subtle
cognitive and memory problems to severe deﬁcits, inevitably ending
in deep dementia. The composite clinical picture at any stage is
variable among AD patients, including cognitive and memory
problems, and mild to severe changes in social behavior with mood
swings and altered personality and character, including apathy,
depression, irritability, agitation, psychosis, aggression.
Current treatments for AD are purely symptomatic and hardly
effective. The development of disease-modifying therapies is ex-
tremely urgent because of the exponential increase in AD with age.
This poses a direct andmajor medical and social threat for current and
all future generations with our ever-increasing life expectancy.Diagnosis of AD is not uniformly accepted or applied, and based on
variable combinations of neurological examination, CSF-biomarkers,
mental and memory tests, MRI and PET brain-imaging. Needless to
state that, even when effective therapy becomes available, diagnosis
of AD should be made as early as possible in the disease process to
help the patient, the family and caretakers.
The development of efﬁcient diagnostic and therapeutic means
relies entirely on scientiﬁc progress made in understanding the
fundamental mechanisms that cause and underlie AD. Progress then
remains heavily dependent on studies in animal models that recapit-
ulate the disease at least in essentials aspects, if not as exact and
complete phenocopies.
Moreover and in addition, early objective diagnosis of AD is essential
for many reasons. Today it is profoundly hampered, if not made
impossible by problems of accuracy and safety, speciﬁcity and
reproducibility of current methods and tests, ranging from cognitive
examination tests, lumbar puncture and ELISA for CSF-biomarkers, PET-
imaging for amyloid load and glucosemetabolism,MRI for brain region-
speciﬁc atrophy. Many tests detect problems (too) late in the disease
process to allow effective treatment, provided it was available.
Diagnostic problems therefore reverberate into therapeutic tests,
because of difﬁculties with recruiting properly diagnosed AD patients,
and of proper stratiﬁcation by genetic, clinical or biochemical
parameters. This is currently technically impossible and prevents
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less costly. The same problems plague experimental therapies that are
hampered by the objective estimation of the rate of decline of cognition.
Finally, stratiﬁcation based on genetic parameters remain largely
limited to deﬁning the ApoE genotype, and is used often only post-
hoc. The many genetic, epigenetic and environmental factors that are
claimed as potential risk-factors to AD are intensely debated, but none
generally accepted or implemented as objective parameters in clinical
studies—with exceptions on the obvious parameter of age and gender.
Despite all the technical progress, the post-mortem brain
pathology described by Alzheimer more than a century ago, still
deﬁnes AD. The microscopic pathology remains the only ﬁnal
diagnosis, unfortunately post-mortem: extracellular amyloid plaques
made up of aggregated amyloid peptides and intracellular neuroﬁ-
brillary tauopathy resulting from aggregated phosphorylated protein
tau. The associated parameter of inﬂammation, also noted by
Alzheimer, remains the third important hallmark in AD brain.
1.2. AD and amyloid
A panoply of data corroborates the amyloid cascade hypothesis
that proposes a primary, causal role for amyloid peptides in the
pathogenesis of AD. The experimental proof is, however, still not
conclusive despite 25 years of molecular and cellular analysis since
the discovery of amyloid peptides [2]. Amyloid peptides (Aβ)
accumulate in the brain of AD patients because of increased
production or of impaired elimination. The peptides are produced
from the amyloid precursor protein (APP) by a complex set of
sequential endoproteolytic cleavages [3].
Amyloidogenic processing of APP is initiated by β-secretase (BACE)
that produces the secreted APPsβ ectodomain and the cell-bound C99
fragment, which is then cleaved by γ-secretase to release the
intracellular domain (AICD). This process also produces various amyloid
peptides for as yet unknown biological reasons, because no physiolog-
ical function is unequivocally assigned to any of the amyloid peptides.
Non-amyloidogenic processing of APP results in the secreted APPsα
ectodomain and the C83 fragment, following cleavage by α-secretase,
an activity exerted mainly by ADAM10 [4]. The C83 fragments are also
processed by γ-secretase to yield the same AICD fragment, but also the
harmless p3 peptides instead of the amyloid peptides [3].
Disease-modifying therapies in clinical tests today are mostly
aimed at reducing the amyloid peptide concentrations in brain, either
(i) by inhibition of β- or γ-secretases, (ii) by increasing elimination by
active or passive immunization, (iii) by preventing peptide aggrega-
tion, or (iv) by increasing proteolytic degradation. Despite the many
drawbacks and problems in these different approaches, the amyloid
peptides remain prime target for therapy, and prime suspects for the
pathogenic mechanism in AD [5].
Interestingly, PET-imaging using speciﬁc amyloid-ligands demon-
strated high amyloid-load in the brain of cognitive non-compromised
elderly and concluded to 20–40% false amyloid-positive cases pending
the study [6–8]. These ﬁndings imply that even brain amyloid load
does not equate to impaired cognition or failing mental capabilities.
1.3. AD and tau: not an innocent by-stander
In contrast to many primary tauopathies, wherein tau is
accountable for neurodegeneration and its consequences, AD is
classiﬁed as a secondary tauopathy downstream of amyloid pathol-
ogy. Protein tau is yet to be generally accepted as being important in
the overall disease process.
Tauopathy is typiﬁed by neuroﬁbrillary tangles and neuropil
treads composed of phosphorylated protein Tau and constitutes the
second post-mortem diagnostic hallmark in AD but in contrast to
amyloid pathology, is not speciﬁc for AD. Tauopathy is diagnostic for avariety of neuro-degenerative diseases that differ widely clinically,
biochemically and pathologically [9–11].
Importantly, tauopathy is invariably present in all AD cases,
including the early onset familial cases (EOFAD) that are associated
with dominant mutations in the genes coding for APP or presenilins.
These presenile AD-cases are by deﬁnition caused by excess
production of deviating amyloid peptides. Consequently, the associ-
ated tauopathy in these obligate amyloid AD cases, must be closely
linked to the cognitive demise and dementia of the Alzheimer type.
Arguably, this is the strongest argument for an essential pathological
contribution of the tauopathy in AD, rather than an innocent by-
stander phenomenon. In addition, long-standing observations main-
tain that the typical brain-regional occurrence and progression of tau
pathology in AD patients correlates temporally and spatially more
closely with neuronal and cognitive dysfunction than amyloid
pathology in AD [12,13].
Interestingly, no familial “amyloid-only” AD-cases have been
described, while more than 40 mutations in the gene coding for
human protein tau (the MAPT gene on chromosome 17) are associated
with many sub-types of frontotemporal dementia [14,15] (cfr www.
alzforum.org). These mutations are either exonic and expressed as a
mutant protein tau, or intronic, which affect splicing of the taumRNA to
include or exclude exon10 that codes for the second microtubule
binding domain. Importantly, intronic mutations produce normal
protein Tau, but at deviating levels, which disturbs physiological
functions that lead to synaptic and neuronal failure and degeneration.
1.4. Protein Tau, microtubule binding and tauopathy
While the amyloid cascade hypothesis [5] emphasizes the impor-
tance of amyloid peptides to the underlying pathology in AD, it does not
provide an explanation for the inherent tauopathy associated with all
AD cases. In addition, as discussed in the previous section, transgenic
mouse with amyloid pathology caused by neuronal expression of any
APP, wild-type or mutant, do not develop authentic tauopathy.
The aggregation of phosphorylated protein Tau into ﬁlamentous
inclusions, eventually tangles, is the characteristic pathological feature
of many neurodegenerative disorders known as Tauopathies, including
Pick's disease, progressive supranuclear palsy, frontotemporal dementia
(FTD) and many others [10,11,16–18]. Familial forms of tauopathy are
associated with exonic and intronic mutations in theMAPT gene coding
for protein tau on chromosome 17 in humans. Themutations are linked
to various subtypes of fronto-temporal dementia, typiﬁed by extensive
tau pathology in frontal and temporal brain regions, largelywithout any
other associated pathology, i.e. no amyloid deposits.
The twomost prevalent isoforms of tau, Tau3R and Tau4R, originate
by alternative splicing of exon10 and have 3 or 4 microtubule binding
repeats [19]. Tauopathies are differentiated biochemically by the ratio of
Tau4R/Tau3R as well as by the relative composition of all tau-isoforms
in the aggregates or tangles. In the case of familial FTD, the associated
mutations are the deﬁning factor, e.g. P301L, G272V, N279K, V337M,
R406W, among others. To understand the mechanisms causing the
familial forms of tauopathy linked to theMAPT gene, wemust deﬁne an
aberration in protein tau that is both needed and sufﬁcient to cause
neurodegeneration — in the absence of amyloid. The eventual
understanding of the problem is even more concerned by the fact that
many intronicmutations in speciﬁed FTD-families are located in intron-
exon splice sites ﬂanking exon10, encoding the second microtubule
binding domain in protein tau. These intronic mutations evidently
produce normal wild-type protein Tau, and their contribution to FTD
can only be a distorted ratio of tau-isoforms in CNS.
The only known physiological action of protein tau is binding to
microtubules, and its afﬁnity is proportional to the number of
microtubule binding domains: Tau4R binds stronger than Tau3R.
Tau3R predominates in embryonic and fetal development, which is
thought to allowgreater plasticity and remodelingof the cytoskeletonof
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are more evident over Tau3R, while adult mouse brain expresses only
Tau4R.Whether the human–mouse difference contributes to the lack of
tauopathy in APP mice remains open for debate.
The expressed exonicmutations resulting in amutant Tau4R protein
that are associated with familial FTD, have been claimed to reduce the
afﬁnity of binding to microtubuli and/or to decrease microtubule
assembly promotion.
Interestingly, the tau-microtubule physiological interaction is
proposed to involve formation of tau homo-dimers [20]. This theoretical
model accounts convincingly for the observed trans-sectional spacing
between microtubules in axons, needed to allow transport of bulky
cargo by themotor proteins. The binding of protein tau tomicrotubuli is
dynamically regulated by a complex pattern of phosphorylation by
different kinases. This reviewdoes not focus on this aspect, although it is
of prime importance for the normal physiological function of protein
tau, and for its deviation in taupathology that is invariably characterized
by excessive tau-phosphorylation [21–25]. The challenge is to deﬁne
among the more than 1011 possible phosphorylated tau combinations
those that tilt protein tau fromMT-bound into semi-crystalline ﬁbrillar
polymer. It must be remembered that protein tau is an extremely
soluble, naturally unfolded protein without a well-deﬁned 3-dimen-
sional structure that withstands boiling and precipitation by chaotropic
agents. But these protein-structural characteristics do not explain the
enigmatic processes that govern its aggregation in the cytoplasm of
neurons in the various tauopathies.
These and other features raise even more questions on brain-
regional differences of tauopathies with their wide variation in
molecular, physical and pathological aspects and with tau-aggregates
that contain either Tau3R or Tau4R isoforms, or mixtures. Moreover,
while we can understand that phosphorylated tau appears in the CSF
of patients as a result of neuronal damage or cell-death, it remains
totally unclear why protein tau is present in CSF of cognitive normal
individuals. These and more questions are to be addressed and
answered in vivo, in suitable animal models.
2. Hypothesis: amyloid, but not alone
The combined evidence positions amyloid peptides as the
initiators or trigger in AD, likely as oligomers and/or small aggregates
that are not exactly deﬁned molecularly and physically.
Protein tau is more and more proposed as a central actor or even
executor of synapses and neurons in AD, largely by extrapolation from
primary tauopathies.
How protein tau exerts its normal physiological function as
microtubule-associated protein and how and why in other conditions,
mutations or changed levels force protein tau to adopt a pathological
role, remains largely to be discovered in vivo.
3. In vivo pre-clinical models
3.1. Problems and solutions, questions and answers
The disappointing outcome of clinical studies aimed to decrease,
curb or neutralize amyloid peptides or their effects, increases the
awareness that effective treatment of AD will not be obtained by
mono-therapy. The AD-problem is vast and variable, and will require
multi-targeted combinational approach, which next to amyloid
proposes tauopathy as obvious target.
To make progress that is physiologically sound, pathologically
relevant and therapeutically effective, we must know physiological
functions and pathological roles of APP and its complex proteolytic
processing. The same holds for protein tau and its intricate web of
kinases and modifying enzymes causing the extensive post-transla-
tional modiﬁcations, not only phosphorylations but also proteolytic
truncation, O-glycosylation, glycation, ubiquitinylation,… Physiolog-ical and pathological contributions are to be deﬁned in the context of
the functions of tau, its interacting partners, its dynamic control and
its turnover. This vast task can be elucidated in appropriate validated
models, and here we concentrate on transgenic mice.
The recapitulation of the typical combined AD-pathology in vivo
closely followed knowledge of molecular mechanisms. The major
challenge is still actual after 20 years of generating transgenic mouse
models that have been invaluable for understanding molecular details
central to AD. Non-mammalian models have been generated to study
cellular pathways and protein interactions that can contribute to the
pathogenesis. Transgenicﬂies, nematodes, zebraﬁsh, lamprey, yeast and
mammalian cells, among others have been generated asmodels for tau-
induced neuro-degeneration, with limited success. These models are
“less complex” than mammals and have offered valuable leads into the
problems at hand, but they do not match the mammalian brain that is
accessible in transgenic mice. The question remains pertinent to what
extentwe can hope to recapitulate the complexity of neuropathological,
cognitive and behavioral features of AD in a small, short-livedmammal.
The question implies whether we should continue to recapitulate AD in
a singlemousemodel, nomatter howmanygenes ormutationswehave
to include or should we study partim–aspects of AD in incomplete
models in vivo [26].
Our research-group generated and characterized over the last two
decades many different single and multiple transgenic mouse strains,
resulting in validated models for amyloid and tau pathology [27–31].
Recently we produced and characterized bigenic APP.V717IxTau.P301L
mice (biAT) as more complete model with synergistic amyloid and tau
pathology in limbic brain regions [32]. The parallel development of the
biGT tauopathy model by combining Tau.P301L and GSK3β mice
deﬁned the essential role of GSK3β in tauopathy [32,33].
We have now extended our armamentarium by including a virus-
based model, using the hybrid adeno-associated viral vector (AAV1/
2) to elicit more rapidly than in transgenic models aspects of amyloid
and tau metabolism in vivo in the hippocampus of wild-type mice
[34]. The outcomewas rather surprising as these AAV-models deﬁne a
major role for protein tau in neurodegeneration.
Here we present and discuss selected aspects of these models in
the context of previously developed and validated transgenic models
for amyloid and tau pathology. We focus this review on speciﬁc
aspects of single and multiple transgenic mice for AD and for
tauopathy alike, rather than drafting an exhaustive list of available
models. We concentrate on lessons that we have learned from the
mouse models and discuss the implications for translating funda-
mental knowledge into clinical, diagnostic and therapeutic applica-
tions. We are convinced that the combination of transgenic with viral
models will contribute to our understanding of molecular, cellular and
system-related pathogenic mechanisms. The models will contribute
to identify therapeutic targets, and allow testing compounds to
eventually treat primary and secondary tauopathies, including AD.
3.2. Older models, older views: mutant APP mice recapitulate amyloid
pathology
Most efforts to generate mouse models for AD were based on the
expression of mutant APP genetically linked to familial early-onset AD
(EOFAD) using various gene promoters in different mouse genetic
backgrounds. Innumerable efforts resulted in many models with
different spatial and temporal expression patterns and even more
important variations in expression levels. Here we discuss these
models only brieﬂy because comprehensive reviews are available
[27,35–39]. An extensive, albeit not complete list of transgenicmodels
for AD can be consulted on-line (www.alzforum.org).
Thewanted characteristic of proﬁcient APP transgenicmouse strains
is robust and predictable amyloid pathology, comparable to amyloid
pathology in AD patients. Amyloid pathologywas and still is considered
widely as themost essential feature of an AD-model. The time-line of its
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intracellular amyloid accumulation in various types of vesicles (Fig. 1).
APP-mice then develop diffuse extracellular deposits and ﬁnally dense
amyloid plaques, usually at an age that exceeds 1 year. Plaques stain
with congo-red, thioﬂavinS and similar compounds with high afﬁnity
for extensive β-pleated sheets of aggregated proteins, similar to AD
brain. Dense focal amyloid plaques are surrounded by dystrophic
neurites and associated with activated glia, typical for inﬂammatory
processes, again as in AD brain. In many models, vascular amyloid
deposits develop subsequent to parenchymal plaques, resulting in
congophilic amyloid angiopathy (CAA) typical for AD brain [29,40,41,
and references therein]. Interestingly,we observed thatmicrobleeds are
dependent on the genetic background of the mice, which is relevant for
the situation in AD patients. Indeed, the incidence of microbleeds and
small vascular accidents varies in different studies. It is evident in no
more than 20-35% of all patients, likely reﬂecting genetic predilection in
individuals at risk for vascular problems.
The amyloid load onset and extent in APP models appears to be
determined most importantly by the level of expression of the APP-
transgene and by the type and number of dominant mutations
incorporated, i.e. up to 5 in some models. Thereby, the relative
concentration of ﬁbrillogenic amyloid peptides in the brain, mainlyFig. 1. Amyloid pathology and tauopathy in brain of transgenic and bigenic mice. Immun
described in studies referred to. (A, B) phospho-Tau with AT100 in frontal cortex (A) and h
frontal cortex (C) and hippocampus (D) of aged biGT mouse [32]. (E) Amyloid with 3D6 in
neuroﬁbrillary tangles (green) in brain of biAT mouse as model for combined AD pathologyindexed as the ratio Aβ42/Aβ40, appears deﬁning for the ensuing
amyloid pathology. Data combined from single and bigenic mice,
incorporating mutant PS1, assigns a major contributions in amyloido-
genesis to Aβ42 peptide as seed and to both Aβ42/40 as bulk material
for amyloid plaques in parenchym. We consider the combination of
mutant APP with mutant PS1 not the most valuable model for amyloid
pathology, nor for its repercussions, because the mechanisms imposed
differ considerably from ageing, which remains themajor risk-factor for
sporadic AD [42].
Remarkably, neuronal expressionofmutant APP is sufﬁcient to cause
not only plaques in the parenchym, but also vascular amyloid
deposition. This supports the hypothesis that amyloid peptides
produced by neurons diffuse in the interstitial ﬂuid and are eventually
drained via perivascular spaces to the blood or cerebrospinal ﬂuid
[29,43,44, and references therein]. The dynamic relation of parenchymal
to vascular amyloid deposits was convincingly corroborated in bigenic
APP.V717I x BACE mice, which produce more of shorter Aβ11-40/42
peptides truncated by excess BACE activity. The N-truncated amyloid
peptides evidently are less soluble and dramatically increased the
parenchymal plaque-load while shunting vascular amyloid [45]. The
data corroborate the hypothesis that temporal and spatial amyloid
deposition in brain parenchyma and vasculature is determined by totalohistochemical staining on ﬂoating sections with speciﬁc monoclonal antibodies, as
ippocampus (B) of terminal Tau.P301L mouse [57]. (C, D) phospho-Tau with AT100 in
cortex of aged APP.V717l mouse [42,49]. (F) Confocal microscopy of amyloid (red) and
[32]. Scalebars all 100 µm, except F 50 µm.
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peptides [44–46]. An important contribution is assigned to ApoE-
lipoproteins in the regional distribution of amyloid in mice [47] and in
AD-patients [48]. This must be analyzed in relevant mouse models to
understand the contribution of ApoE to the overall AD problem, an
aspect that is outside the scope of this review.3.3. Amyloid mice lack tauopathy and neurodegeneration
The most marked feature of all APP transgenic models with
amyloid pathology is their complete lack of authentic tauopathy. At
best, phosphorylation of endogenous mouse protein tau in dystrophic
neurites surrounding amyloid plaques was observed in brain of APP
mice, but no ﬁbrillar tau aggregates or tangles [27,29,49]. Tauopathy
was not considered obligatory in an AD model, nor expected per se,
although predicted by the amyloid cascade hypothesis that should
apply also to mouse models. The cognitive normal individuals with
high amyloid load identiﬁed by PIB-PET imaging, are then predicted to
still lack tauopathy and thereby escape dementia. These individuals
do not qualify as AD-cases but are interesting to deﬁne the genetic
make-up that prevents amyloid pathology to induce tauopathy.
Whether this is a temporary condition, with tauopathy merely
delayed, or a permanent state makes these “amyloid-escapees” not
less interesting.
The lack of tauopathy in APP transgenic models is a drawback, but
an even greater setback for the amyloid cascade hypothesis. The
“amyloid-only” condition does not elicit tauopathy and thereby fails to
produce AD, which is deﬁned as the combination of both pathologies.
This problem was and is insurmountable for all model-makers who
failed to deliver a complete pathology model for AD by expression of
mutant or wild-type APP in mouse forebrain neurons in vivo. The
conundrumwas eventually solved in bigenic and triple transgenicmice,
by the extra incorporation of mutant tau transgenes, which evidently
does not conform to the genetic situation of any AD patient.
On the other hand, the available “amyloid-only”mice have been and
remain highly informative for the differential analysis of various
molecular, systemic and pathological aspects of the generation of the
amyloid peptides, of their physiological and pathological contributions
and repercussions on cognition and on AD-related defects in adult and
ageing mouse brain. We have used our APP.V717I mice extensively in
that respect, including many combinations with transgenic and knock-
out mice to probe the contribution of relevant genes, i.e. presenilin1/2,
BACE, ADAM10, ApoE4, Tau, A2M, GSK3, among others [27–33].
Straightforward, obligatory characteristics of AD models are defects
in behavior and cognitive performance. Various cognitive tests used to
evaluate transgenic APPmice range from thewater-maze, to other types
of mazes, over fear-conditioning and novel object recognition tasks.
Overall, APP mice exhibit more or less strongly impaired cognition,
although not consistent or similar in all paradigms in all models. The
general conclusion is that an overload of amyloid peptides and/or APP-
metabolites negatively affect synaptic functioning and plasticity. One
important variable, however, is the age of onset of the cognitive deﬁcits,
i.e. before, concomitant with or after the deposition of amyloid plaques.
In APP.V717I mice, we have dissociated the early cognitive defects from
the later amyloid plaque pathology, which was the ﬁrst report that
stepped away from amyloid plaque deposition as the cause of impaired
cognition in a living ADmodel [49]. The venue proved attractive for the
development of alternative views on the cognitive decline in AD and for
a revised or extended amyloid cascade hypothesis [5].
The issues surrounding amyloid peptides and plaques remain food
for academic debate and more. Elimination of excess amyloid peptides
fromneurons and synapses bydeposition asparenchymal plaques could
be a ﬁrst means of protection. This can however not be a long-term
effective strategy because increasing physical protein deposits in any
organ can never be an efﬁcient route of elimination, as demonstrated byatherosclerotic plaques, gall and kidney stones, immunoglobin light
chain aggregates, serum amyloid, and many other instances.
Importantly, the observation of the early phenotype in APP.V717I
and other amyloid mice effectively dissociated amyloid plaques as the
direct cause of cognitive demise. The implication is that impaired
cognition must be attributed to amyloid peptides proper, in chemical
or physical forms other than plaques. The hypothesis has now gained
wide acceptance and experimental support in the identiﬁcation of Aβ-
oligomers as responsible for functionally disturbing synaptic trans-
mission, also in vivo. Nevertheless, the actual composition and
number of peptides, their molecular nature and conformation in the
presumed faulty Aβ-oligomers, are all but well known. Nor do we
understand yet their mode of action in vivo, nor the receptors to
which they bind speciﬁcally or not, notwithstanding the considerable
progress in describing their effects on cognitive parameters in vivo.
This brief paragraph constitutes a dense concentrate of the problems
that overshadow the amyloid-cognition-AD relation. The issues are
vast and surpass the scope of this review.
Finally, despite tentative claims to the opposite, “amyloid-only”
transgenicmousemodels do not suffer substantial neurodegeneration
in limbic regions, not even at old age, which sets them apart from AD
patients. Ageing is evidently a relative issue, particularly in mice.
Neurodegeneration typiﬁed by death of neurons is responsible for the
progressive brain atrophy in later stages of AD, which could be merely
a matter of time inherent to the longer duration of the disease in
humans. Consequently, only initial stages of AD can be recapitulated
in mice and perhaps we should aim only for that in mouse models.
Alternatively, neurodegeneration can be recapitulated by othermeans
and in other types ofmodels, whichwe have approached previously in
a conditional p25 mouse model [50] and most recently in AAV-Tau
based models [34]. The AAV-based models unexpectedly provided
important clues to the responsible action of wild-type Tau4R and to
the mechanisms involved, as discussed below.
3.4. Tau transgenic mice, models for Tauopathy and neuroﬁbrillary
tangles
Available transgenic mice that model tau-mediated neurodegen-
eration rely on the expression of wild-type tau isoforms or of mutants
implicated in familial tauopathies. The variable success and the
problems are reviewed in detail [24,25,27,28,37–39,51,52]. Here, we
limit our overview to selected models with explicit tauopathy that are
informative for the questions raised in the previous sections.
Transgenicmice that express a single isoformofwild-typehumanTau
ranged from the shortest Tau3R/ON to the longest Tau4R/2 N. Most
markedly, mice that express wild-type tau developmotor problems that
are associated with axonopathy. The eventual brain and spinal cord
pathology usually includes aberrant phosphorylation but never robust
and authentic tauopathy deﬁned as aggregates, ﬁbrils and tangles.
Noteworthy, introduction of the entire human MAPT gene in the mouse
genome led to expression of all six human tau isoforms in neurons
[53,54]. Eventually, redistributionof protein Tau fromaxons to cell bodies
led to formation of tau aggregates and cell death at very old age.
Extremely interestingwas theobservation that degeneratingneuronsdid
not contain tau aggregates, explicitly interpreted by the authors to “…
suggest that cell death can occur independently of NFT formation” [54].
Tau4Rmicewehavegenerated followed the rule: severe axonopathy
developed ﬁrst in hindbrain, brainstem and spinal cord, resulting in
severe clasping of hind legs. In homozygous Tau4R offspring this was
already obvious at weaning [55]. The axonopathy was typiﬁed
pathologically by axonal dilatations, leading to wallerian degeneration
and muscle wasting [55]. The phenotype was aggravated by treatment
of Tau4R mice with lithium salts, and rescued completely by co-
expression of GSK3β in bigenic mice [56]. These data not only identiﬁed
this important role of GSK3β, but was also the ﬁrst experimental
demonstration of GSK3β as efﬁcient tau-kinase in brain in vivo [56].
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phosphorylated at crucial phospho-epitopes by GSK3, the bigenic
Tau4RxGSK3β mice did not develop tauopathy. We concluded that
GSK3 is essential but not sufﬁcient tau-kinase in neurons to cause
tauopathy in vivo [56], subsequently borne out in the biGTmice [32,33].
Transgenic mice expressing protein mutant tau associated with
FTDP-17 are in general successful in producing authentic tauopathy
with neuroﬁbrillary tangles, eventually even neurodegeneration
[24,25,28,37–39,51,52]. We generated Tau-P301L transgenic mice
that develop profound tauopathy, that was moribund in contrast to
the Tau4R mice, despite very similar spatial and temporal expression
at similar protein tau levels [55,57]. Their typical age-dependent
cognitive and motoric defects have been observed also in other
mutant tau transgenic mouse strains, resulting in authentic tauopathy
although variable in intensity and in brain-region in expressing
mutant tau, e.g. Tau-P301L [57–61], Tau-R406W [62–64], Tau-V337M
[65,66], Tau-P301S [67,68], Tau-N279K [69] (reviews [37–39]).
Nevertheless, tauopathy in these mouse models must be considered
closer to FTD than to AD tauopathy, which imposes restrictions when
used in pre-clinical tests of treatments speciﬁc for AD.4. Newer models, newer views
4.1. Bigenic and multiple transgenic mice as more complete AD-models
Because single transgenic mice failed to recapitulate comprehen-
sively the complete AD pathology, the development of multiple
transgenic mice was regarded essential to gain deeper insight in the
pathogenesis of AD. Most early models of this type were combinations
of mutant APP and mutant PS1 that have been instrumental to
delineate the contributions of γ-secretase activity to amyloid peptide
generation and amyloid pathology. This overview is not primarily
concerned with those aspects and models, but remains concentrated
on the relation amyloid-tau pathology.
The most multigenic mouse model for AD co-incorporates mini-
genes coding for mutant APP.SW and for Tau.P301L in the genome of
PS1.M146V knock-in mice. These Triple tg or 3xTg mice progressively
present with amyloid pathology, ﬁrst intracellularly followed by
diffuse and eventually senile plaques, alongside tau phosphorylation
ending in tauopathy with neuroﬁbrillary tangles [39,70].
Similar to our APP.V717I mice, the 3xTg mice suffer cognitive
impairment and problems with memory, synaptic dysfunction and
diminished LTP before the deposition of amyloid plaques [39,70]. These
defects correlate with the accumulation of intraneuronal Aβ, again like in
APP.V717I mice [42,49]. Immunotherapy of Triple tg mice with an
amyloid-based vaccine diminished the amyloid pathology but also the
early, althoughnot the late taupathology,whichwas claimed toproblems
with proteasomal degradation [39]. The amyloid cascade hypothesis
appeared tobe respectedbecause thedata indicated that tanglepathology
was subordinate to or a consequence of amyloid peptides.
Somewhat unfortunately, the strategy used to generate the 3xTg
mice prevents direct comparison to single transgenic parental mouse
strains. That type of comparison was used proﬁciently in the bigenic
model combining JNPL3(TauP301L) x Tg2576 (APP.SW) mice. These
bigenic mice develop amyloid deposits like the parental Tg2576 mice
and exhibit tauopathy even in excess of the parental JNPL3 mice
[58,71]. We crossed our Tau.P301L mice that develop moribund
tauopathy [57,60] with our APP.V717I mice that develop amyloid
pathology [44,49]. The resulting biAT mice present robust amyloid
and tau pathology with amyloid plaques in forebrain and NFT in
pyramidal neurons of hippocampus and cortex, starting at age 10-
12 months and becoming established as AD-like pathology around
age 13-15 months, comprising diffuse and senile amyloid plaques,
intra-neuronal tangles in cortex and hippocampus, amyloid angio-
pathy and inﬂammation [32].The detailed time-line of brain pathology and biochemistry of the
biAT mice and the associated phenotypical and cognitive features
relative to the parental single transgenic mice is ongoing. The amyloid
pathology in biAT mice is very similar in aspects and timing, but more
intense, as in the parental APP.V717I mice that lack overt tauopathy
[27,42,44,49]. In contrast, the tauopathy of biAT mice is dramatically
enhanced in the hippocampus and cortex relative to the parental Tau.
P301L mice. These data expose the marked synergism between the two
major AD-pathologies n the limbic system of the biAT mice [32,33].
Surprisingly, the moribund brainstem pathology typical for the Tau.
P301L mice, is largely alleviated despite the combined AD-like
pathology, with a marked increase in the life-span of the biAT mice.
Somewhat serendipitously, the underlyingmechanismwas highlighted
by the bigenic Tau.P301L x GSK3β-S9A mice, based on the same Tau.
P301L strain in combinations with the overexpressing GSK3β mice,
characterized before [56,57]. The biGT mice develop the most dramatic
forebrain tauopathy reported in any transgenic model [32]. NFT
accumulate massively in nearly all cortical and hippocampal neurons
that become packed with ﬁlamentous and ﬁbrillar aggregates in ageing
biGT mice of 15–18 months old (Fig. 1). They provide pathological and
biochemical evidence that GSK3β contributes essentially to phosphor-
ylation of protein tau in vivo, causing tau-aggregation in neuronal cell-
bodies and processes, causing neuronal dysfunction, although not
neuronal death [32,33].
Beginning amyloid pathology already activates both GSK3 iso-
zymes by tyrosine phosphorylation in young APP.V717I mice [32,33].
Thereby, both GSK3 isozymes contribute to increased phosphoryla-
tion of protein tau, and eventually feed back onto APP processing.
Remarkably, however, the resulting pathological outcome differs in
different brain-regions. Both biAT and biGT mice have increased
tauopathy in limbic regions, but both show alleviation in brainstem
and spinal cord relative to the parental Tau.P301Lmice [32,33,72]. The
positive effect of amyloid and GSK3 on survival in biAT and biGT mice
is attributed to the markedly diminished tauopathy in the autonomic
control centers in the brainstem. This hypothesis is being substanti-
ated in vivo, by electrophysiological analysis of the brain-stem and by
plethysmography [72].
Time-line analysis demonstrates that the early activation of both
isozymes in the parental APP.V717I mice correlates with increased
phosphorylation of tau already at young age [32]. Consequently, the
correlated appearance of intracellular Aβ, activated GSK3 isozymes
(tyrosine phosphorylation) and increased tau-phosphorylation im-
pinge on the cognitive defects also evident at young age [49].
The data underline that amyloid is up-stream of tauopathy in vivo,
in support of the amyloid cascade hypothesis. Note, however, that the
APP.V717I and biGT mice are in fact EOFAD models, which leaves the
quest for factors upstream of amyloid pathology in late onset and
sporadic AD open. The models further underline the important
contribution of GSK3β, and possibly of, the GSK3α isozyme, following
their increased tyrosine phosphorylation in young APP.V717I mice.
GSK3 isozymes can become phosphorylated on Y279/Y216 by auto-
phosphorylation or by tyrosine kinases such as Fyn or Abl. The actual
mechanism, and the effect of amyloid, remains unexplained and
unexplored in vivo.
In conclusion, the comparative analysis of the two bigenic strains,
biAT and biGT, revealed the striking similarity in the progression of
tau phosphorylation and tauopathy, and in the resulting clinical
outcome. The data position GSK3 as central player in the complex web
that relates amyloid and tau pathology. Whether this also reﬂects a
physiological link remains to be unraveled experimentally.
4.2. Viral AAV-APP.SLA model: amyloid pathology without
neurodegeneration
Over the last decades invaluable insight in the molecular, physio-
logical and pathological aspects of AD-related proteins has been
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multiple transgenic mice, outlined in previous sections. The efforts
needed to generate, select and characterize the most informativemodels that we now retain, have been substantial while their
implementation in pre-clinical studies requires major efforts. These
and other reasons, including pressure from patients and relatives, and
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others to explore alternative options formore rapid andﬂexiblemodels.
Viral vectors are attractive to express proteins of interest in deﬁned
brain regions, both experimentally and for gene therapy in humans.
Here we discuss in brief recent developments and ﬁndings in a model
that recapitulates the important feature of tauopathy, i.e. tau-mediated
neurodegeneration, which is largely lacking in transgenic models.
Adeno-associated virus (AAV) vectors have been proposed for
gene delivery in CNS because of the safety and unique aspects. Most
humans are populated with AAV and the virus persists in humans for
long periods without apparent negative consequences. Recent
technical progress has improved some earlier short-comings of AAV
as experimental vectors and graded them up to an excellent delivery
vehicle in experimental medical research [73,74]. We ﬁrst aimed to
use AAV vectors to recapitulate AD-like pathology in wild-type mice.
AAV-particles with chimeric capsids of serotype 1/2 express the
embedded transgenes under the control of the human synapsin1 gene
promoter in pyramidal hippocampal neurons in vivo [75,76].
Wild-type mice were injected intracerebrally with AAV-particles
and robustly expressed either wild-type human APP or with a
designed APP.SLA triple mutant, harboring the Swedish, London and
Austrian mutations. The APP.SLA mutant, but not wild-type APP
caused progressive accumulation of APP-metabolites including amy-
loid peptides in pyramidal neurons in hippocampus CA1/2-regions
and in deep layers of the cortex. From 3 weeks post-injection (p.i.)
onwards, intracellular amyloid accumulated in vacuolar and granular
bodies in CA1/2 pyramidal neurons, evolving to diffuse, cell-
associated amyloid accumulations. Eventually at 6 months p.i.,
authentic amyloid plaques were deposited over the hippocampal
area and nearby cortex (Fig. 2). Interestingly, amyloid pathology was
associated with increased phosphorylation of endogenous protein
mouse tau at residues T181 and T231, which phospho-epitopes
deﬁned by antibodies AT270 and AT180, respectively. Loss of neurons
remained marginal, even at 6 months p.i. of AAV-APP.SLA when
increased phosphorylation of protein tau was evident [34]. When not
wild-type but young Tau.P301L mice were injected with AAV-APP.
SLA, not only amyloid plaques but also tau-aggregates developed at
6 months p.i. (unpublished observations). These and ongoing studies
are needed to complement and extend observations with lentivirus-
mediated expression of Tau.P301S in APP23 mutant mice [77]. The
novel AAV-based tau and amyloid models corroborate observations in
transgenic amyloid mouse models that recapitulate the amyloid
pathology of AD with only minimal or no neurodegeneration [49].4.3. Viral AAV-Tau model: pyramidal neurodegeneration without
tauopathy
In sharp contrast, very similar manipulations to express either wild-
type Tau4R or mutant Tau.P301L resulted in extensive neurodegenera-
tion and loss of pyramidal neurons in CA and adjacent cortical layers
already at 3 weeks p.i. (Fig. 2). Interestingly, a very similar outcomewas
observedwith AAV-Tau4R, extending the neurotoxic effect towild-type
human Tau4R. Both observations were unexpected, and analyzed in
widely differing directions to gain insight in themechanismof neuronal
death in this model.Fig. 2. Intracerebral injection of AAV-vectors in wild-type mice: neuro-degeneration without
Intracerebral injection inwild-typemiceofAAVvectors analyzed3 to 24 weekspost-injection. (
amyloid at 3 weeks p.i. (antibody 3D6). Scale bar 20 µm. panel b: additional extracellular diffu
24 weeks p.i. (antibody 3D6). Scale bar 25 µm. panel d: amyloid plaques at 24 weeks p.i. (his
24 weeksp.i. Scale bars50 µm. (B) Pyramidal cells inhippocampus at24 weeksp.i (antibodyNeu
Scale bars 0.5 mm. Note normal appearance in AAV-APP.SLA injected mice, except for small sec
injected mice. (C) Similar neurodegeneration in AAV-Tau.P301L and AAV-Tau.4R injected mic
reveals neurons with degenerating nuclei in AAV-Tau injected mice at 3 weeks p.i.. Scale ba
(antibodies AT8, AT180, AT270) in AAV-Tau.P301L injected mice at 3 weeks p.i.. Scale bars 0.5Firstly, neurodegenerationwasnot due tomassive overexpression of
humanprotein tau. The actual levels in hippocampal extractswerenear-
physiological and only about twice those of endogenous mouse Tau4R.
Thiswas similar to the AAV-APP.SLAmodel,where hippocampal human
APP.SLA were about twice those of endogenous murine APP, but which
failed to cause neurodegeneration. Expression of EGFP by a similar AAV-
vector proved harmless to pyramidal neurons over long time-periods
[34]. The data excluded that overexpression of any protein by these
vectors caused the observed neurodegeneration, and qualiﬁes the
observed pyramidal cell-death as speciﬁc for human protein tau.
Because the conclusion holds also for wild-type Tau4R, the model
conforms to observations in familial FDT: intronic and exonicmutations
cause similar clinical outcome by expression of wild-type or mutant
Tau4R, respectively (cfr backgroundSection1.4). The contributionof the
tau-mutations to the mechanism of tau-neurotoxicity awaits a rational
explanation in human FTD patients.
Secondly, intracerebral injection of 3- or 10-fold lower doses of
AAV-Tau with consequently lesser expression of human protein tau,
produced more graded and less rapid loss of hippocampal neurons.
The AAV-tau induced neurodegeneration is thereby further demon-
strated to be directly caused by, and proportional to the near-
physiological levels of protein tau.
Thirdly, protein Tau became phosphorylated at many pathological
epitopes, with AT8, AT180, AT270 as most evident. But increased
phosphorylation did not lead to appreciable deposition of Tau-
aggregates in the degenerating pyramidal neurons before they were
lost. Biochemically, more loose aggregates were observed by western
blotting following non-reducing SDS-PAGE. High Mr tau-containing
complexes migrated in an extensive smeared pattern, that resolved
into the normal banding pattern of protein tau (∼64–70 kDa) upon
disulﬁde bond reduction [34]. These high Mr complexes apparently
are disulﬁde bonded and partially SDS-resistant, which is further
examined biochemically.
Interestingly, preliminary experiments with a similar expression
of a C-truncated version of wild-type protein tau, lacking the entire
microtubule binding domain, proved harmless and did not induce
neurodegeneration. The inherent implication that microtubule bind-
ing of protein tau is essentially involved in the degenerative
mechanism, oriented our further analysis to mechanisms that involve
microtubuli, i.e. axonal transport and cell cycle. The former is of
paramount importance for neurons, while the latter is an evident
problem for post-mitotic neurons.
Also of note, microgliosis was intense and spatially and temporally
closely associated with AAV-Taumediated degenerating neurons [34].
This was most recently also reported in a similar rat model aiming at a
different pathology in a different brain-region [78]. We observed
previously a very similar correlation in an unrelated transgenic model
for hippocampal sclerosis, with neuronal death provoked by inducible
expression of p25, the truncated activator of cdk5 [50]. Also in that
model the intense neurodegeneration and brain atrophy was not
accompanied by aggregation of protein tau. The data conﬁrmed that
cdk5 activated by p25 or p35 is not an effective tau-kinase in mouse
brain in vivo [50,79]. In yeast models we actually observed the
opposite, because not overexpression but inactivation of the pho85
kinase, the yeast orthologue of mammalian cdk5, strongly promoted
phosphorylation and aggregation of tau [80].tangles by AAV-Tau and amyloid pathology without neurodegeneration by AAV-APP.SLA.
A)Various stages of amyloid pathology inAAV-APP.SLA injectedmice. panel a: intracellular
se amyloid at 12 weeks p.i. (antibody 6E10). Scale bar 20 µm. panel c: amyloid plaques at
tology with compound X-34). Scale bar 25 µm. panels e, f: phosphorylated mouse tau at
N) inwild-typemice injectedwithAAV-APP.SLAorAAV-Tau.P301Lmiceor sham-injected.
tion in CA2 as opposed to severe neuro-degeneration in CA and cortex of AAV-Tau.P301L
e at 3 weeks p.i. (NeuN antibody). Scale bar 0.5 mm. Right panels: hematoxylin-staining
rs 40 µm. (D) Expression of human Tau (antibody HT7) and selected phospho-epitopes
mm.
Fig. 3. Schematic representation of inter-relations between APP/amyloid, GSK3 and protein tau. The central incorporation of GSK3α/β, with inhibitory S21/S9 and activating Y279/
216 phosphorylations, is discussed in the text, based essentially on our ﬁndings in single and bigenic mice [32]. The various connections are primarily distilled from in vivo
observations in transgenic mice and represent proven (solid arrows) or proposed effects (broken arrows). Tau-P* represents the hypothetical intermediate form of phosphorylated
protein tau in a transitional conformational state that directs it either into aggregation or towards neuronal toxicity. The orange colored Tau-P* box reﬂects its proposed ambivalent
status in provoking neurotoxicity or aggregation, i.e. danger or relative safety. The resulting formation of neuroﬁbrillary tangles (NFT) is purposely meant to be a neuronal safety
measure, which is reﬂected by its green background. NFT-formation constitutes a temporary solution to reduce levels of Tau-P*, but can evidently not be considered a long-term-
solution, as proven in tauopathy patients. The molecular factors and mechanisms behind the decision of neurons to develop tauopathy as NFT rather than suffer neurodegeneration
and cell death, is not understood as discussed in the text. The contribution of kinases and phosphatases is evident, as opposed to that of extraneous X-factors that are various and
many, i.e. genetic, epigenetic, environmental, nutritional, educational, social, … The unknown factors can act on many of the shown relations and connections, but for clarity we
included them only at the most intricate control points in the scheme. The Tau-P* intermediates are the central molecular species in the overall process, acted upon by the additional
unknown factors that can vary both in origin and in type, i.e. neuronal, microglial, mitochondrial, cell-cycle control kinases, protein-folding chaperones, heat-shock proteins,
cytokines, growth factors,… The impact of various different actors leads to various and variable clinical and pathological symptoms, as observed in AD and particularly in tauopathy
patients. A tentative time-line from mild cognitive impairment (MCI) to the ultimate deep Alzheimer dementia typiﬁed by severe brain atrophy, is suggested schematically, not
taking into account the deposition of amyloid plaques, because we consider these as cognitively inert, at least initially, as discussed.
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We have schematically summarized the combined ﬁndings in
different mouse models to depict the various players and their
interrelations (Fig. 3). The main axis conforms with the amyloid
cascade hypothesis, whereby accumulation of amyloid is the main
trigger in AD and leads to tauopathy. Central in this scheme, and in our
work-hypothesis, is GSK3 supported by the ﬁnding that amyloid
activates both GSK3 isozymes by tyrosine phosphorylation, and these
contribute essentially to tau-phosphorylation [32,33]. The important
inter-connections in the scheme are based on in vivo observations in
transgenic mice, as discussed in foregoing sections. Note that GSK3 is
linked to cognition by its other, inhibitory type of phosphorylation at
Serine9 [81].
The data allow to propose that the differential phosphorylation of
protein tau is directly linked to the differential pathological outcome,
either slow aggregation or rapid degeneration. On the one hand,
severe neurodegeneration is evident without appreciable tau-aggre-
gation in the AAV-Tau and p25 models [34,50]. On the other hand,
tau-aggregation and tauopathy is not accompanied per se by marked
neurodegeneration in transgenic biAT and biGTmice [32,33]. We pose
that any imbalance in the physiological activities exerted by Tau and
GSK3 causes functional deﬁcits that eventually lead to synaptic,
axonal and neuronal degeneration, as observed in models in vivo
(reviews [82]) and sustained by genetic evidence [83].
Based on the combination of models, we further defend the thesis
that neurodegeneration is the outcome of dual actions, beginningwith endogenous damage by mal-formed proteins like protein tau, or
α-synuclein, huntingtin, undigested or undigestible proteins in
storage diseases, cholesterol-transport proteins, and others. A second
factor is nevertheless as essential, which can be neuronal or
microglial, related to oxygen-supply, glucose-overload or shortage,
cholesterol metabolism or other essential metabolites. This thesis
ﬁnds support in observations by us and others, referred to throughout
this review. Moreover, the data now convincingly demonstrate that
large protein-aggregates are not the direct nor even essential cause of
neuronal death, illustrated again by recent observations that tangle-
bearing neurons survive despite membrane damage due to tauopathy
[84]. These propositions imply a larger number of potential combina-
tions of damaging factors that in turn dictate the number of ways a
neuron can die, a problem not yet solved [85]. The data thereby still do
not answer the “chicken-and-egg-question” in tauopathy: phosphor-
ylation, aggregation, neuro-degeneration [24].
In the scheme (Fig. 3) the Tau-P* acronym represents a
hypothetical, unidentiﬁed intermediate form of phosphorylated
protein tau, either a single molecule or a small aggregate that is
either not bound to microtubuli, or bound in an abnormal aggregated
mode [80]. Tau-P* most could mark a transitional, but also a more
stable conformational molecular state or form. These elusive Tau-P*
molecules that we propose are faced with two options: aggregate or
not, with similar ﬁnal outcomes but different time-lines. The ﬁrst
option is to aggregate rapidly and thereby to be effectively neutralized
as neurotoxic factor. Nevertheless, tau-aggregates solve the problem
only temporarily because over a longer period of time, tau-aggregates
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concept in the tau-ﬁeld.
Alternatively, when aggregation is prevented by X-factors (Fig. 3)
or not prompted, the Tau-P* species persist and cause cellular damage
from within neurons, or from the outside after secretion, by as yet
unknownmechanisms.We realize that these actions andmechanisms
are counter-intuitive and not conform accepted cell-biological
dogmas. They comprise and involve several unresolved issues, not
in the least the molecular logic that underlies the decision made by
neurons to develop either tau-aggregates or succumb. The Tau-P*
intermediates are proposed to play a central role in this process,
evidently acted upon by factors that can vary in origin from activated
microglia to damaged mitochondria, over cell-cycle control kinases
and heat-shock proteins. The relative spatial and temporal impact of
these different players then produces the various clinical symptoms
and pathological hallmarks, typical for tauopathies and AD. These
competing or complementing processes deﬁne eventually the time-
line and progression from mild cognitive impairment to deep
dementia with severe brain atrophy, typical for the terminal stage
of Alzheimer's disease (Fig. 3).
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